<DOC>
	<DOCNO>NCT02400476</DOCNO>
	<brief_summary>An Open-Label Study Characterize Incidence Severity Diarrhea Patients Early-Stage HER2+ Breast Cancer Treated Neratinib Intensive Loperamide Prophylaxis</brief_summary>
	<brief_title>A Study Looking Incidence Severity Diarrhea Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib Loperamide</brief_title>
	<detailed_description>An open-label , Phase 2 study investigate incidence diarrhea HER2+ breast cancer patient receive neratinib intensive loperamide diarrhea prophylaxis , alone combination anti-inflammatory treatment , previously undergone course trastuzumab therapy adjuvant setting Patients receive : - Neratinib 240 mg orally daily thirteen ( 13 ) 28-day cycle - Loperamide daily two ( 2 ) 28-day cycle need , loperamide 1 cycle [ 28 day ] start treatment group receive colestipol Amendment 4 , need thereafter - Either anti-inflammatory treatment 1 cycle ( patient enrol start Amendment 3 ) , bile acid sequestrant treatment 1 cycle ( start treatment group receive colestipol Amendment 4 )</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Bismuth subsalicylate</mesh_term>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<mesh_term>Colestipol</mesh_term>
	<criteria>1 . Aged ≥18 year sign informed consent 2 . Histologically confirm stage 1 stage 3c primary adenocarcinoma breast 3 . Documented HER2 overexpression geneamplified tumor validate approve method 4 . Patients must complete course prior adjuvant trastuzumab experience side effect result early discontinuation trastuzumab since resolve 5 . The last dose trastuzumab must give &gt; 2 week ≤1 year ( 365 day ) enrollment 6 . Clinical radiologic assessment negative local regional recurrence disease metastatic disease time study entry , include Bone scan positron emission tomography ( PET ) scan ; require alkaline phosphatase ( ALP ) ≥2 x upper limit normal ( ULN ) and/or symptom metastatic bone disease . A confirmatory image study require result bone scan questionable Computed tomography ( CT ) , magnetic resonance imaging ( MRI ) ultrasound abdomen chest ; require aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ALP ≥2 x ULN Chest radiograph 7 . Left ventricular ejection fraction ( LVEF ) ≥50 % measure multiplegated acquisition scan ( MUGA ) echocardiogram ( ECHO ) 8 . Eastern Cooperative Oncology Group ( ECOG ) status 0 1 9 . Negative βhuman chorionic gonadotropin ( hCG ) pregnancy test premenopausal woman reproductive capacity ( biologically capable child ) woman less 12 month menopause . [ Women consider postmenopausal ≥12 month without menses , absence endocrine antiendocrine therapy . ] 10 . Women childbearing potential must agree commit use highly effective nonhormonal method contraception , ie , intrauterine device , bilateral tubal ligation , vasectomized partner , abstinence ( preferred lifestyle patient ) , time informed consent 28 day last dose investigational product . Men female partner childbearing potential must agree commit use highly effective method contraception ( ie , method hormonal contraception associate inhibition ovulation ) treatment 3 month last dose investigational product 11 . Recovery ( ie , Grade 1 baseline ) clinically significant AEs relate prior therapy ( exclude alopecia , neuropathy , nail change ) 12 . Provide write , inform consent participate study follow study procedure 1 . Clinical radiologic evidence local regional recurrence disease metastatic disease prior time study entry 2 . Currently receive chemotherapy , radiation therapy , immunotherapy , biotherapy breast cancer 3 . Major surgery within &lt; 30 day start treatment receive chemotherapy , investigational agent , cancer therapy , except hormonal therapy ( eg , tamoxifen , aromatase inhibitor ) , &lt; 14 day prior initiation investigational product 4 . Active uncontrolled cardiac disease , include cardiomyopathy , congestive heart failure ( New York Heart Association functional classification ≥2 ; include individual currently use digitalis , beta blocker , calcium channel blocker specifically congestive heart failure ) , unstable angina , myocardial infarction within 12 month enrollment , ventricular arrhythmia 5 . QTc interval &gt; 0.450 second ( male ) &gt; 0.470 ( female ) , know history QTc prolongation Torsade de Pointes ( TdP ) 6 . Screening laboratory assessment outside follow limit : Absolute neutrophil count ( ANC ) &lt; 1,000/μl ( &lt; 1.0 x 109/L ) Platelet count &lt; 100,000/μl ( &lt; 100 x 109/L ) Hemoglobin &lt; 9 g/dL Total bilirubin &gt; 1.5 x institutional upper limit normal ( ULN ) ( n case know Gilbert 's syndrome , &lt; 2 x ULN allow ) Creatinine Creatinine clearance &lt; 30 mL/min ( calculate CockcroftGault formula Modification Diet Renal Disease [ MDRD ] formula ) 7 . Active , unresolved infection 8 . Patients second malignancy , adequately treat nonmelanoma skin cancer , situ melanoma situ cervical cancer . Patients nonmammary malignancy must diseasefree least 5years 9 . Currently pregnant breastfeed 10 . Significant chronic gastrointestinal disorder diarrhea major symptom ( eg , Crohn 's disease , malabsorption , Grade ≥2 National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events Version 4.0 [ CTCAE v.4.0 ] diarrhea etiology baseline ) 11 . Clinically active infection hepatitis B hepatitis C virus 12 . Evidence significant medical illness , abnormal laboratory finding , psychiatric illness/social situation could , Investigator 's judgment , make patient inappropriate study 13 . Known hypersensitivity component investigational product ; know hypersensitivity salicylates ; know hypersensitivity aspartamecontaining product patient phenylketonuria ; know allergy medication component medication use trial 14 . Unable unwilling swallow tablet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HER2 +</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Neratinib</keyword>
</DOC>